|
gptkbp:instanceOf
|
antiviral drug
nucleoside analogue reverse transcriptase inhibitor
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J05AF05
|
|
gptkbp:bioavailability
|
>80%
|
|
gptkbp:brand
|
gptkb:Combivir
gptkb:Epivir
gptkb:Epivir-HBV
gptkb:Kivexa
gptkb:Trizivir
|
|
gptkbp:CASNumber
|
gptkb:134678-17-4
|
|
gptkbp:chemicalClass
|
pyrimidine analogue
|
|
gptkbp:combines
|
gptkb:dolutegravir
gptkb:abacavir
gptkb:zidovudine
tenofovir
|
|
gptkbp:developedBy
|
BioChem Pharma
|
|
gptkbp:discoveredBy
|
Bernard Belleau
|
|
gptkbp:eliminationHalfLife
|
5–7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1989
|
|
gptkbp:hasMolecularFormula
|
gptkb:C8H11N3O3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lamivudine
|
|
gptkbp:IUPACName
|
(2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
|
|
gptkbp:KEGGID
|
D00219
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reverse transcriptase
|
|
gptkbp:MedlinePlusID
|
a696011
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
229.26 g/mol
|
|
gptkbp:patent
|
1995
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
<36%
|
|
gptkbp:PubChem_CID
|
CHEMBL122
54809
60825
DB00709
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sells
|
gptkb:ViiV_Healthcare
GlaxoSmithKline
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
fatigue
headache
cough
insomnia
hepatomegaly
lactic acidosis
|
|
gptkbp:UNII
|
2T8Q726O95
|
|
gptkbp:usedFor
|
HIV infection
chronic hepatitis B
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|